ABBOTT LABORATORIES acquires St. Jude Medical, Inc.
Snapshot
ABBOTT LABORATORIES acquired St. Jude Medical, Inc. for approximately $25 billion equity value ($46.75 cash + 0.8708 Abbott shares per share, ~$85/share; ~$30 billion total value including debt) in January 2017. The transaction was structured as combination (cash and stock). St. Jude Medical, Inc. is a St. Paul, Minnesota, USA-based Medical devices — cardiovascular & neuromodulation business.
- Acquirer
- ABBOTT LABORATORIES
- Target
- St. Jude Medical, Inc.
- Value
- approximately $25 billion equity value ($46.75 cash + 0.8708 Abbott shares per share, ~$85/share; ~$30 billion total value including debt)
- Date
- January 2017
- Type
- full acquisition
- Status
- ready
The deal at a glance
About this deal
ABBOTT LABORATORIES acquired St. Jude Medical, Inc. for approximately $25 billion equity value ($46.75 cash + 0.8708 Abbott shares per share, ~$85/share; ~$30 billion total value including debt), a transaction completed in January 2017, structured as combination (cash and stock).
St. Jude Medical, Inc. operates in Medical devices — cardiovascular & neuromodulation, is based in St. Paul, Minnesota, USA. St. Jude Medical is a global medical device company with leading positions in cardiac rhythm management, atrial fibrillation, heart failure and neuromodulation.
The combined business will have a powerful pipeline ready to deliver next-generation medical technologies and offer improved efficiencies for healthcare systems, creating a premier medical device leader.
Industry-leading cardiovascular and neuromodulation pipeline complementary to Abbott's existing vascular and diagnostics franchises. Abbott projected approximately $500 million of annual pre-tax synergies by 2020. Integrated into Abbott's Medical Devices business
No advisory firms have been disclosed for this transaction.